Early immunotherapy using autologous cells to reverse the effect of anti-pancreatic islets in recently diagnosed diabetics
Material/Methods: The procedure was approved by the Institutional Ethics Committee. In 2014, in three young patients, type 1
diabetes mellitus diagnosis was confirmed, with the presence of positive antibodies and ketoacidosis. Three
patients were given autologous bone marrow stem cell stimulated with filgrastim through cell puncture, as immune modulators.
One patients was treated with conventional diabetes treatment and participated in this experiment as a control group. The families of the patients signed the informed consent. For this test, no specific statistical analysis was applied.
The patients were less than 10 years old, diagnosis of type 1 diabetes for less than 60 days, body mass index less
than 21 kg/m2, normal complete blood count, coagulation and renal function, no lesions in target organs, glycosylated
hemoglobin (HbA1c) level less than 13.10%, c-peptide level less than 0.57 ng/ml, positive results of
Islets Cells Antibody (ICA), Glutamic Acid Decarboxylase (GAD) and insulin antibody.
Results: In four patients treated, the follow up at 12 months showed negative value in ICA, GAD and anti insulin antibody
levels, with an increased levels of c peptide and decreased levels of blood glucose and HbA1c.
Research Conclusions: Treatment with autologous marrow derived cells is easy and effective as it reversed the production and effect
of anti pancreatic islet antibody and significantly resulted in an increased c-peptide concentration.